Patients aged ≥ 16 years from an adult CF centre undertook adherence measures by medication possession ratio (MPR) and self-report and were assigned to one of three adherence categories (<50%, 50-<80%, 80% and above) by their composite score (MPR).
Introduction
Advances in early diagnosis and treatment of cystic fibrosis (CF) have resulted in significant improvements in survival with many patients living into adulthood and middle age. [1, 2] This success has been achieved through specialised multidisciplinary care in combination with intense treatment regimens which are time consuming and negatively impact on daily life. Poor adherence to treatment remains a significant problem, being as low as 40 to 50%. [3] [4] [5] [6] [7] Adherence problems can negatively influence health outcomes such as pulmonary exacerbations, [8] health related quality of life, [3] and healthcare costs; [6] [7] [8] [9] trends that are also apparent across other respiratory diseases. [10] [11] [12] Consensus regarding the accurate measurement of adherence is lacking and has proved difficult in day-to-day practice. The use of subjective self-report, supported by objective measures including pharmacy collection, medication possession ratio and chipped hardware such as the ineb, [4] are frequently used as part of good practice in reporting study findings. While all of these have inherent limitations, [7] objective physiological measures that might define adherence more accurately are lacking.
Studies in other chronic diseases have recently highlighted the association between variation in physiological measures such as blood pressure [13] [14] [15] and immunosuppressive therapy [16] and adherence to medication. These provide objective measures, which may help to characterise poor adherence and trigger interventions to support better outcomes. Attention has focused on the variability of lung function as an improved predictor of lung decline in CF, above that of FEV1 alone; the hypothesis being that it is a more sensitive marker that may reflect exacerbations, individual pulmonary variation, and adherence. [17] In CF there is evidence that low rates of medication adherence are associated with increased pulmonary exacerbations. [8, 18] Given the maintenance effect of medications such as nebuliser therapies on respiratory function, it is therefore plausible that poor adherence might be associated with greater variation in lung function. A variability measure that accounts for natural changes, exacerbations and individual variation over time might also provide greater predictive accuracy than studies that have shown an association between adherence and the single measure of baseline FEV1. [8] In the day to day management of patients with CF we have recognised apparent differences in the fluctuation of lung function, weight and infection markers in patients known to have poor adherence. Patterns in diseases such as these have only become apparent following implementation of a disease-specific electronic patient record containing rich clinical 'real time' diagnostic, biochemical, anthropometric, pulmonary function and pathology data. [19] This detailed longitudinal data which is routinely displayed graphically has provided a basis for testing whether variation indices might predict adherence within a population with CF.
The aim of this study was to characterise adherence in a large adult population with cystic fibrosis and to test the hypothesis that increased variation in lung function was an indicator of poor adherence to treatment.
Methodology
Participants: Patients attending a large regional adult cystic fibrosis unit were recruited from December 2012 to August 2013. Participants were identified from an electronic register of 400 patients, of 16 years and over, who had a diagnosis of CF as defined by the presence of a positive clinical phenotype with either two CF-causing mutations and/or two positive sweat tests.
Participants were consecutively invited to participate in the study as they attended a routine outpatient visit at a time of clinical stability. Patients attended every 2-3 months, in line with local policy. Exclusion criteria included pregnancy, neurological disease, malignancy and renal disease to avoid potential influences on adherence patterns.
Measures:
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) for the preceding 12 months were recorded. Each was measured using a calibrated, compact spirometer (Vitalograph, UK) undertaken by an experienced physiotherapist, and using the best value from a series of at least three attempts in accordance with guidelines. [20] In addition, age, gender, genotype, baseline weight (kg), height (m), BMI (kg/m 2 ), Vitamins A, D, E, C-reactive protein (CRP), number intravenous antibiotic treatment days within the last year were recorded.
Coefficient of variation (CoV) for FEV1 was calculated by extracting all consecutive highest then lowest values for FEV1 for 6 and 12 months prior to baseline from the electronic health record.
These time scales were chosen to align with pharmacy retrieval data CoV FEV1 (6 months) and to examine the impact of longer term patterns of variation on adherence CoV FEV1 (12 months).
The total, mean and standard deviation of all values for FEV1 for each participant was calculated.
The equation for coefficient of variation for FEV1 was then calculated according to standard deviation FEV1/mean FEV1. Coefficient of variation for weight and CRP were similarly examined.
Adherence measures
Pharmacy collection: Individual medications and prescribed days of treatment were retrieved from the EHR for the time period ≤ 6 months prior to the baseline index date; a time scale chosen to enable greater comparability with the level of self-reported adherence reported by the DMI-CF disease specific questionnaire. [7] Community pharmacy details were abstracted from the EHR and participants gave contact details for all other community pharmacies used within this time period. A letter of request was sent to all pharmacies together with a copy of the patient's signed consent form requesting amount medication prescribed for ≤ 6 months prior to the baseline index date. Up to 2 repeat requests were made by phone to maximise prescription data return.
Similarly for patients using the i-neb, the prescribed number of doses was also retrieved from the EHR and medication uptake then downloaded from the ineb ≤ 6 months prior to the baseline index date. Patient MPR was then adjusted for all medications prescribed during inpatient admission and any out-patient prescriptions issued from the ward. The MPR was calculated from at least two prescription collections for each individual medication and then averaged to obtain a composite MPR. Medication possession ratio (MPR) was calculated using the equation, medication dispensed divided by the number days medication prescribed, multiplied by 100.
Adherence self-report: For each participant, a record of all routinely prescribed medications was generated at baseline from the electronic health record. All subjects completed a Disease Management Interview-CF (DMI-CF) self-report adherence questionnaire at baseline. [7] Percentage adherence to each prescribed medication was then calculated by dividing the reported dose by the prescribed dose for the each of the following medications and treatments; airway clearance, recombinant DNase, bronchodilators, inhaled steroids, pancreatic enzyme replacement therapy, nutrition, oral nutritional supplements or nasogastric/gastrostomy feed, vitamins, oral antibiotics, inhaled antibiotics and insulin.
A composite adherence measure was calculated, omitting airway clearance, nutrition and insulin fpr self-report to enable a composite measure comparable to adherence by MPR. Composite adherence was calculated as the sum of all medications patients prescribed on the electronic record, divided by the total number of self-reported medications taken. Patients were assigned to one of three categories according to adherence reported by MPR, [< 50% adherence, 50 < 80% adherence and 80% and above]; a classification used in previous research in CF. [8] Ordinal regression was used to identify univariate predictors of adherence for testing in a multivariate model, using coefficient variation measures 6 and 12 months preceding baseline respectively. Genotype was defined as 3 categories (Delta F508 homozygous, Delta F508 heterozygous and 'other'). Only univariate variables with a p value of <0.1 were used in the multivariate model. A forwards and backwards stepwise fashion process was used to construct a final model. 
Results

Participant characteristics:
Of 267 patients invited to participate in the study, 250 subjects were enrolled, 17 declined to participate (15 citing that they did not want to participate in this specific study and 2 citing that they did not wish to participate in studies in general). A further participant withdrew prior to analysis (n=249). Of this number, pharmacy refill data were obtained for 106 patients.
With the exception of presence of diabetes, no differences were observed in characteristics between those with pharmacy refill data and those without (Table 1) Adherence by MPR was subsequently used in further analysis. Baseline characteristics are shown in Table 2 . Participants were predominantly homozygous for the delta F508 mutation and had good nutritional status. Clinical and demographic characteristics were similar between adherence categories (MPR) ( 
Univariate and multivariate analysis:
In an unadjusted ordinal model, predictors of adherence (MPR) were age, number of medications prescribed, body mass index, CoV FEV1 (6 months preceding), Vitamin D and E (Table 3) . Following a stepwise regression, CoV FEV1, number of medications, and BMI remained significant (Fig 3) . The odds of being in a higher adherence category increased with every unit of BMI, each 1% reduction in CoV FEV1, and each additional medication [ Fig. 3 ]. This was replicated using CoV FEV1 (12 months preceding). The underlying mechanism for the predictive value of CoV FEV1 was not addressed in the current study but may reflect poor disease control, reduced adherence to physiotherapy and nebulised therapy. Delays in patients seeking medical intervention at times of exacerbation may also be important, as it is not infrequent for patients with poor adherence to dramatically improve their lung function during hospital admission, resulting in larger variation in lung function than is seen in those who enter treatment at an earlier stage.
It can be argued that in patients with asthma, where lung function is routinely used as an objective measure of airways obstruction, the disease is also characterised by a high degree of variability demonstrated by peak flow (PF) and FEV1 falling abruptly on treatment withdrawal. In contrast, CF is associated with endobronchial infection, mucus retention and to a lesser extent airway hypersensitivity. The withdrawal of inhaled corticosteroids in patients with CF without asthma appears to have no impact on change in lung function, antibiotic usage and rescue bronchodilator. [22] It suggests that the variation in lung function in this study is not explained by the diurnal variation or hyper responsiveness reported in asthma.
Weight loss may occur as a result of reduced adherence to pancreatic and oral supplements and Conversely studies of smaller sample sizes have indicated a positive impact of age [24] whilst acknowledging the wide variation between individuals. Our own results indicate that adherence improves with age and suggests that interventions to improve adherence should be targeted towards those in early adulthood.
A significant predictor of adherence in the overall models were number of medications prescribed. This relationship was replicated when adherence was measured according to selfreport [Supplementary Table 1] . As adherence category improved, patient medications rose from associate treatment burden with barriers to adherence, [25, 26] but agrees with findings by
Quittner et al who reported a positive association between medication regimen complexity and adherence. [9] However their proposal that a more complex regimen may be a proxy for disease severity and a greater willingness to undertake prescribed medication, was not borne out in our own study. Whilst an upward trend in disease severity was observed, this was not significant, nor was there a difference in intravenous antibiotic treatment days different across adherence categories. Others have also shown that high treatment burden is independent of disease severity. [27] Why increased medication may be associated with improved adherence in our study is therefore unclear. We hypothesise that increase treatment burden may reflect improved clinical control especially as it is our practice to stop or change medications in partnership with patients in response to poor treatment uptake. It is not infrequent that the team stop all treatment in patents with very poor adherence in order to start again, adjusting therapy accordingly. Another possibility is that some individuals are "resilient" and have developed specific coping strategies that enable them to perform this complex regimen on a regular basis.
Adherence measured by MPR was consistently below that measured by self-report with a mean discrepancy of 14% for the composite scores. Similar trends are consistent in the literature, although there is little consensus as to how it might best be addressed in reporting data. Quittner et al. have advocated triangulation of data with at least 2 measures employed, integrated through regression analysis into a single index. [7] We chose to report adherence by MPR and self-report measures, noting that neither provide a definitive measure of adherence. The discrepancies observed agree with previous reports in adult cohorts; physiotherapy being the least frequently adhered to treatment (49%), and pancreatic enzyme replacement therapy the best (91%). [28] In general adherence to respiratory treatments was poorer than to nutritional therapies suggesting that challenges in improving treatment uptake have changed little in 20 years.
Adherence (MPR) was a composite measure assimilated from core medications that were present on an established questionnaire, the DMI-CF. [7] It.is probable that each medication or treatment has a different weighting of importance both within and between patients. In turn this highlights the complexity of developing a valid adherence index measure for wider use. It is also likely that the composite measure used within this study might be reduced to contain fewer medications, although consensus is lacking as to what this might be.
The study has several limitations inherent to all studies examining adherence through crosssectional design and reliant on current methods of adherence measure. Firstly, adherence is known to be a fluid measure, changing over time and by treatment component. [29, 30] Measurement is complex and although MPR is considered a more accurate measure of adherence than self-report, it has inherent limitations associated with changes in prescription and medication carryover. The former was partially accounted for within the study by accurate prescription data documented within the EHR system against which prescription collection could be aligned. For treatments such as pancreatic enzyme replacement therapy where patients selftitrate against differing snack and meal content, this is less useful and whilst average daily intake of PERT was obtained and documented, error is likely. MEMS data, considered the 'gold standard' can provide greater accuracy, [31] but has inherent costs and its own bias if doses are removed but not consumed. It has led to a recognition that measurement technique and that studies should incorporate more than one measure. [7] Our own results demonstrate concordance between both measures of adherence and enabled patterns of objective measures of adherence to emerge that can inform future adherence interventions and predictive variables that can be further explored to aid evaluation.
The measure of lung function itself is also prone to error. We sought to minimise this through a standardised approach to measurement of pulmonary function within the clinic setting, where trained physiotherapists undertook all measures in line with current guidance. [20] In healthier subjects FEV1 is also known to lack sensitivity in detecting early change, when in fact lung damage is present. [32] The threshold for variation to occur may therefore be different in early compared to moderate and late disease despite similar levels of poor adherence and this requires further study. In future research the more sensitive lung function clearance index may add further value and accuracy in determining smaller changes in lung function measurement.
[33]
The study also has a number of strengths. Electronic clinical records that contain data captured in 'real time' enabled accurate extraction of all FEV1 data points for calculation of CoV FEV1. [17] As a measure CoV FEV1 provides an average of lung function dispersion values over time, making use of longitudinal data that can be incorporated into a single index. This is considered important in future studies, in a move away from 'snapshot' values that may contribute to bias. Importantly the final model was robust meeting the validity criteria for ordinal regression and achieving a model of good fit.
Conclusion:
Coefficient of variation FEV1 is a significant predictor of adherence. This novel marker of adherence requires further evaluation across treatment regimens and duration of treatment.
